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Polyostotic ﬁbrous dysplasia (FD) associated to McCune-Albright Syndrome (MAS) often leads to fractures, deformities, and
bone pain resulting in bad quality of life. Parenteral bisphosphonates have been used in children and adolescents to improve these
symptoms with few adverse eﬀects. We evaluated the response to oral Alendronate in a girl with severe MAS FD and observed
improved quality of life with reduction of bone pain.
1.Introduction
McCune-Albright Syndrome (MAS) is a rare disease pre-
senting with the classical triad of polyostotic ﬁbrous dys-
plasia (FD), skin hyperpigmentation (caf´ e-au-lait spots) and
endocrine dysfunction, usually seen as precocious puberty
in females. The mosaicism of mutations in the GNAS1 gene
results in hyperactive Gsα protein which causes activation
of hormonal receptors and bone dysplasia [1–3]. There is
increased osteoclastic activity, which can be detected by the
elevation of biochemical markers of bone turnover, and
normal bone marrow architecture is progressively replaced
by abnormal ﬁbrous tissue [4, 5].
bisphosphonates, antiresorption agents, largely used in
thetreatmentofosteoporosishavebeentriedasanoptionfor
improvement of FD symptoms in MAS [6–9]. Most patients
are treated with intravenous pamidronate, in a hospital
regimen, or as outpatients in clinic settings. Alendronate
(ALN) is a second-generation bisphosphonate that has, as
an advantage, oral administration. It has been used for
treatment of several disorders related to increased bone
resorption; however, it is rarely used by the pediatric
population.
Since we could not ﬁnd reports on the use of oral ALN
in children with FD of MAS, although we are aware of an
ongoing, as yet unpublished, study with children [4], we
present the case of a girl with MAS treated during a one-year
period with oral ALN.
2.CaseReport
A 10.5-year-old white girl was admitted with complaints of
severe weekly headache, diplopia, and nasal obstruction. She
also had daily bone leg pains which caused frequent school
absenteeism. She was in outpatient followup since she was
20 months old when it was noticed caf´ e-au-lait spots. By
the age of 3 years she presented with left exophthalmos,
and a severe form of FD of skull, which leads to the
diagnosis of MAS. She had already undergone left optical
nerve surgical decompression at 5 years of age and a second
procedure was under consideration. At 6 and 10 years of
age she was submitted to two turbinectomy procedures;
however, she still had complaints of nasal obstruction. She
did not present endocrinopathies or bone fractures episodes.
When she was 7 years old she was treated twice with
intravenous Pamidronate, 1mg/kg/d during 3 days in a 62 International Journal of Pediatric Endocrinology
month interval, and had presented vomiting and headache
during the infusion. In-between these two treatments she
received 10mg/day of oral ALN for 30 days which was
well tolerated. At 9 years of age she presented pubertal
development (B2 Tanner stage).
Shewasborntononconsanguineousparents(Wt:3000g;
Ht: 48cm). She had a healthy brother. Her father and two
uncles had caf´ e-au-laitspots, and her mother had high blood
pressure and anxiety disorder.
Physical examination showed severe craniofacial defor-
mity, left proptosis and large caf´ e-au-lait spots with irregular
borders in the left scalp and sacral region. Her weight was
36kg (+1 SD) and height was 136.2cm (0 SD); Body mass
index was normal (BMI: 19.73 Kg/m2; 75centile); she had
a BP of 90/60 mmHg and B3 P2 Tanner stage. She was
very upset with the bone pain and impaired quality of life,
especially regarding school absenteeism, and a limited trial
with oral ALN was prescribed.
Two and a half months before the ALN trial she had
undergone screening for endocrinopathies (FT4: 1.0mg/dL
(RV: 0.8–1.9), TSH: 1.35mUI/mL (RV: 0.4–5.0), PRL:
2.2ng/mL (RV: 1.9–25), Cortisol: 13.9ng/dL (RV: 5.0–25)—
RV:Referencevalue)andrenalphosphatewasting,whichwas
absent.GHlevelsafteroral75gdextrosewerenormal.Serum
calcium, phosphorus, 25–OH Vitamin D and PTH levels
were normal (Table 1). Bone scintigraphy revealed typical
pattern of polyostotic FD with intense uptake in facial bones,
right femur, right arm and ribs. DEXA showed normal total
body bone mineral density (BMD: 0.907g/cm2; +0.09 SD).
ComputerizedTomographyofskullshowedﬁbrousdysplasia
lesions without signs of increased intracranial pressure.
Biochemical markers of bone turnover, alkaline phosphatase
and 24-hour urinary hydroxyproline levels were elevated.
Blood count, electrocardiogram and serum liver enzymes
were normal.
3. ALN Treatment
After the patient andher mother signed an informed consent
form, ALN (70mg tablets with 200ml of water) was admin-
istered once a week, initially under medical supervision. She
was advised to be fasting and remain upright for at least 30
minutes following ingestion of the drug. After two weeks, the
patient continued medication at home, with no diﬃculties.
ALN treatment was interrupted for 15 weeks (between 8 and
29 weeks of followup) due to a complaint of muscle pain
and dysphagia during the postoperative period of her third
turbinectomy. She also presented mild self-limited dyspepsia
with no need for treatment interruption.
Throughout her followup visits she repeatedly reported
feeling better and not having missed any more classes.
Improvement was also evaluated through a numeric pain
scale where the perception of pain varied from 0 to 10. Pain
perception went from an intensity of 8 to 5 following 7
months of treatment. After 10 months of treatment the pain
intensity was 3 and after 12 months of treatment she felt no
pain. She presented menarche 5 months after the beginning
of the medication. Growth velocity was of 6cm/y associated
with proportional advancement of bone age during the 2
year study (CA: 11y3m and BA: 11y). Sclerotic bands in
the left wrist metaphyses were observed on plain X-ray, after
treatment.
Improvement during ALN treatment was also attested
by the lowering of urinary hydroxiproline levels during
followup and near complete normalization of alkaline phos-
phatase (Table 1).
She was treated with ALN for a year and the beneﬁts
lasted during the year following the end of treatment. At her
last visit she was 14 years old; she was clinically stable and felt
no pain. The results of a new screening for endocrinopathies
did not show abnormalities.
4. Discussion
The primary and likely only eﬀect of bisphosphonate treat-
ment observed in MAS patients is the reduction or complete
resolution of bone pain. Reduction of bone fractures, no
harm to linear growth or altered fracture healing and
better quality of life have been described [6, 10, 11]. Until
now, the majority of pediatric patients received parenteral
pamidronate [6, 11–16]; however, there is no consensus on
the eﬀectiveness of this treatment [7, 17].
Chapurlat et al. found that almost 50% of patients had
radiological improvement of lesions as well as increase in
cortical thickness and ﬁlling of lytic lesions [12].
Improvement of bone pain may be explained by the
antiosteoclastic action of the drug, with reduction of
cytokines and other pain-related substances released by the
lesions. Furthermore, improvement of bone mineral density
may occur due to inhibition of bone resorption leading to
improvement of surgical outcome in MAS patients treated
with bisphosphonates, yet a controversial issue [4, 14].
ALN is a biphosphonate which is largely used in the
treatment of osteoporosis in adults [18] and osteogenesis
imperfecta in children [10, 19]. It was related to satisfactory
improvement of bone pain and less aﬀected sites in the
scintigraphy scan in some reports [8, 20].
ALN oral administration is considered to be safe and
well tolerated. Most common adverse eﬀects are upper
gastrointestinal, mainly, esophageal irritation, which can
be prevented with special care during the administration.
Headache, diarrhea, intestinal constipation and atrial ﬁbril-
lation may also occur [21–23]. Recently there were reports
of esophageal cancer with oral bisphosphonate use in adult
patients [24]. Sclerotic bands, observed in wrist metaphyses
on plain X-ray, are often described in the literature and
appear to have no clinical implications [25]. There is also
some concern about longer-term possible side eﬀects of
bisphosphonates on future pregnancies of treated females
[15].
Instead of classical daily administration, the new thera-
peutic regimens such as 70mg/weekly dose given to adults
has also been used in children with osteogenesis imperfecta
(according to the weight) with good tolerance [10]. The
70mg/weekly dose administered to this girl was based on
treatment protocols that have been used in pediatric patientsInternational Journal of Pediatric Endocrinology 3
Table 1: Biochemical markers of bone metabolism.
Weeks of
followup
PTH 25 OHD Ionized Ca Total Ca P ALP Urinary 24h hydroxyproline
0 39.2 79.4 NA 9.0 4.2 852 ∗112
8 NA NA 1.25 9.3 NA 864 NA
29 57.7 NA NA 8.5 3.9 798 ∗214
47 70.6 NA NA 9.6 4.0 608 NA
61 61.7 NA 1.12 8.9 3.6 585 ∗∗9.4
RV 10–69 pg/mL 14–80ng/mL 1.12–1.32 mmol/L 8.4–10.2ng/dL 2.5–4.5ng/dL 50–530UI/L
∗12–58mg/24h
∗∗70–140mg/24 h
N A :n o ta v a i l a b l e ;R V :r e f e r e n c ev a l u e ;C a :c a l c i u m ;P :p h o s p h o r u s ;A L P :s e r u ma l k a l i n ep h o s p h a t a s e .





no well-deﬁned criteria for precise indication and response
to treatment. Diﬀerent parameters for treatment suspension
in children with osteoporosis have been reported: BMD Z
Score ≥− 1 SD; reduction of 50% in fracture incidence;
resolution of bone pain (the most useful indicator of
treatmenteﬀect)oroccurrenceofadverseeﬀects[19,21,27].
There is no consensus on the changes in the markers
of bone turnover during bisphosphonate therapy. Alka-
line phosphatase (bone formation marker) and urinary
hydroxyproline (bone resorption marker) are indicators
of severity and activity of osseous lesions in MAS [4].
Lowering of the biochemical markers of bone resorption is
more pronounced than the changes in formation markers
after bisphosphonate treatment [21, 22, 27–29]. There are
reports of signiﬁcant reduction in alkaline phosphatase,
osteocalcin,urinaryhydroxyprolineandurinaryNTXduring
bisphosphonate use[12]. However, reference values for some
of these biochemical markers are not well established in
the pediatric population mainly because their increment
could be a reﬂection of the normal bone growth and
remodeling processes [1]. Although we noticed a trend
towards normality in our patient biochemical markers it is
not possible to foresee if there will be a sustained beneﬁcial
eﬀect to treatment. There are reports of improvement in
BMD persisting for 2 years after interruption of intravenous
bisphosphonate treatment in children with osteogenesis
imperfecta [19]; biochemical markers of bone turnover were
normal after 6–9 months of treatment [27].
Until standard criteria for treatment interruption have
been established we believe the endpoint should be clinical
improvement. Improvement of bone pain and of daily activ-
ities including reduction in school absenteeism, showing an
increase in quality of life were the criteria which deﬁned
interruption of treatment in the present paper.
We considered the outcome to have been favorable
although it is still not possible to predict its endurance or
reproducibility.
We concluded that weekly ALN regimen was a good
option for improving symptoms of FD of MAS in this girl,
due to ease of administration and lack of severe adverse
eﬀects reported in the patient. We also believe there is
an urgent need for ongoing studies addressing the many
unanswered questions regarding the use of bisphosphonates
in pediatric patients, in order to safely use this medication.
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